source
- AstraZeneca reportedly bids $10 billion for metabolic biotech Rhythm PharmaceuticalsAstraZeneca is said to have made a $10 billion offer to acquire Rhythm Pharmaceuticals, a biotech that develops treatments for rare neuroendocrine disorders. The proposal values Rhythm at $124 per…
- Medicare to slash 340B drug payments and expand site-neutral rules in 2027Medicare finalized a rule that will cut payments for drugs covered by the 340B discount program and broaden site-neutral payment policies beginning in 2027. The rule is expected to reduce Medicare…